BeiGene
BGNE
#881
Rank
โ‚น1.860 T
Marketcap
โ‚น16,946
Share price
1.71%
Change (1 day)
5.70%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Cash on Hand

Cash on Hand as of June 2024 : โ‚น217.50 B

According to BeiGene 's latest financial reports the company has โ‚น217.50 B in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

BeiGene - Cash on Hand chart (from 2014 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31โ‚น264.26 B-29.58%
2022-12-31โ‚น375.25 B-23.91%
2021-12-31โ‚น493.16 B45.24%
2020-12-31โ‚น339.55 B385.41%
2019-12-31โ‚น69.95 B-43.55%
2018-12-31โ‚น123.91 B131.72%
2017-12-31โ‚น53.47 B113.74%
2016-12-31โ‚น25.01 B274.72%
2015-12-31โ‚น6.67 B137.65%
2014-12-31โ‚น2.80 B1057.97%
2013-12-31โ‚น0.24 B

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
โ‚น1.37 B-99.37%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น3.40 B-98.43%๐Ÿ‡บ๐Ÿ‡ธ USA